Risk for myocardial infarction or stroke lower with testosterone therapy among men with hypogonadism and other cardiovascular risk factors
Study reveals that almost 90% of men have hypogonadism at the time of hospital admission for COVID-19.
Testosterone undecanoate therapy reduces NAFLD grade in obese men with functional hypogonadism and type 2 diabetes
It is unclear whether low testosterone is a marker or a mediator of severe and impending severe COVID-19 illness.
Each 1 unit increment in Dietary Inflammatory Index was associated with a 4.0% increase in the odds of testosterone deficiency.
Kyzatrex is an investigational, oral testosterone undecanoate softgel that utilizes lymphatic absorption and phytosterols to increase bioavailability and provide a favorable pharmacokinetic profile.
Bone loss in patients with kidney stone disease, particularly in men, has been underappreciated in clinical practice, according to investigators.
Additional safety data on testosterone therapy are needed before it can be used to prevent type 2 diabetes.
In a study, most symptomatic hypogonadal men treated with Natesto, a short-acting 4.5% nasal testosterone gel, attained normal testosterone levels at 6 months while preserving sperm counts.
Jatenzo® (testosterone undecanoate; Clarus Therapeutics), an oral testosterone replacement therapy, is now available for the treatment of hypogonadism.